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Abstract
Background: This study was designed to determine the role of the A1 adenosine receptors in intracerebral hemorrhage
(ICH)-induced secondary brain injury and the underlying mechanisms.
Methods: A collagenase-induced ICH model was established in Sprague–Dawley rats, and cultured primary rat cortical
neurons were exposed to oxyhemoglobin at a concentration of 10 μM to mimic ICH in vitro. The A1 adenosine
receptor agonist N(6)-cyclohexyladenosine and antagonist 8-phenyl-1,3-dipropylxanthine were used to study the
role of A1 adenosine receptor in ICH-induced secondary brain injury, and antagonists of P38 and Hsp27 were
used to study the underlying mechanisms of A1 adenosine receptor actions.
Results: The protein level of A1 adenosine receptor was significantly increased by ICH, while there was no significant
change in protein levels of the other 3 adenosine receptors. In addition, the A1 adenosine receptor expression could
be increased by N(6)-cyclohexyladenosine and decreased by 8-phenyl-1,3-dipropylxanthine under ICH conditions.
Activation of the A1 adenosine receptor attenuated neuronal apoptosis in the subcortex, which was associated with
increased phosphorylation of P38, MAPK, MAPKAP2, and Hsp27. Inhibition of the A1 adenosine receptor resulted in
opposite effects. Finally, the neuroprotective effect of the A1 adenosine receptor agonist N(6)-cyclohexyladenosine was
inhibited by antagonists of P38 and Hsp27.
Conclusions: This study demonstrates that activation of the A1 adenosine receptor by N(6)-cyclohexyladenosine could
prevent ICH-induced secondary brain injury via the P38-MAPKAP2-Hsp27 pathway.
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Background
Intracerebral hemorrhage (ICH) is a frequent cause of
mortality (estimated mortality rate ~ 50 %) and morbid-
ity (accounts for ~ 10–15 % of all strokes) during the
perioperative period and may cause patient paralysis or
even death [1, 2]. Progression of the pathophysiology of
ICH is still not very well understood [3, 4]. However,
there is a general consensus that hemorrhage in the
brain [5] leads to tissue disruption and displacement [6].
A series of secondary pathophysiological processes, which
are referred to as secondary brain injury (SBI) [7], includes
ischemia of brain tissue surrounding the hematoma, de-
velopment of brain edema [8, 9], activation of apoptotic
programs [10, 11], and toxic effects of the hematoma [12–
14]. Finding treatments that relieve the pathophysiology of
ICH has challenged neurosurgeons for many years.
As a potent biological mediator, adenosine has been
reported to be extensively released during hemorrhage
and eliminated quickly from plasma by the uptake
mechanism and adenosine deaminase [15]. And both the
uptake and the deamination are effective in removing
extracellular adenosine and regulate the activation bal-
ance of adenosine receptors [16]. All the four adenosine
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receptor subtypes, including A1, A2a, A2b and A3, can
be stimulated by extracellular adenosine when its con-
centration reaches the micromolar range [17]. It has
been reported that adenosine deaminase activity in the
poor-grade subarachnoid hemorrhage (SAH) patients
was higher than that in the good-grade SAH patients
[18]. In recent years, evidence has shown that the
adenosine receptors, particularly A2a adenosine receptor
(A2aAR), are of critical importance in hemorrhagic
stroke [19]. A2aAR has been shown to be involved in
the beneficial effect of 17beta-estradiol in attenuating
SAH-induced apoptosis and vasospasm [20]. And
A2aAR agonism is effective in preventing SAH-induced
vasospasm. However, global inactivation of A2aAR could
confer protection against the early ischemic vascular in-
jury after SAH, suggesting that early inhibition of
A2aAR after SAH might reduce cerebral injury. As
shown above, the previous studies are mainly focused on
the role of A2aAR in SAH-induced brain injury, which is
controversial and may be selectively manipulated by tar-
geting different cellular elements [19]. Besides, the posi-
tive roles of A1AR in SAH-induced vasospasm [21] and
A2aAR in ICH-induced proinflammatory events and cell
death have been reported. However, the effects of the
four adenosine receptor subtypes on ICH-induced SBI
still remain elusive and must be clarified.
Mitogen-activated protein kinase (MAPK) family, in-
cluding extracellular signal-regulated kinase (ERK), p38,
and Jun N-terminal Kinase (JNK), widely mediates in-
flammation, cell proliferation, and apoptosis. As the acti-
vation of MAPK pathways by A1 [22, 23], A2a [22, 24,
25] and A2b [22, 26] and A3 [22] adenosine receptors
has been demonstrated, the involvement of this intracel-
lular phosphorylative cascade in adenosine receptor
regulation has attracted more and more attention. A1AR
mediated p38 MAPK activation plays a crucial role in
the presynaptic inhibitory effect of adenosine on CA3–
CA1 synaptic transmission [27]. A1AR-mediated p38
MAPK and JNK activation is a crucial step in regulating
AMPAR trafficking during prolonged hypoxia [28]. Hu-
man adenosine A1, A2A, A2B, and A3 receptors
expressed in Chinese hamster ovary cells all mediate the
phosphorylation of ERK [23]. Elucidating the signaling
pathway involved in the action of adenosine receptors will
facilitate the understanding of death or survival mecha-
nisms in ICH and the development of targeting drugs.
In addition, it has been pointed out that differences in
the efficacy of adenosine receptors may be caused by dif-
ferences in expression. Overexpressions of adenosine re-
ceptors can lead to signal transductions that do not
occur in cells with the receptors expressed at a normal
level [29]. In the present study, we tested the time
course of the expression of the four adenosine receptor
subtypes and evaluated the effects of ICH on these
parameters. We hypothesized that pharmacological ago-
nists selective for adenosine receptors would provide
neuroprotection following ICH. Our results demon-
strated that, among the four adenosine receptor sub-
types, only the protein level of A1AR was significantly
increased in rat brain after ICH and oxyHb-treated neu-
rons, while the other three receptors have no significant
changes. 48 h after ICH, activation of A1AR by R-PIA




We first performed a time course experiment (Fig. 1).
After establishment of the ICH model, rats were killed
at the following time points after induction of ICH: 0 h,
6 h, 12 h, 24 h, 48 h, 72 h, and 1 week. In western blot
analysis, compared with the other adenosine receptors,
A1AR levels varied the most (Fig. 1a and b). In contrast
to the group subjected to ICH, the sham group
expressed a low level of A1AR. After induction of ICH,
the level of A1AR increased with time, peaking at 48 h,
and then decreased. Consistant with the in vivo data,
western blot assay showed that the protein level of
A1AR in cultured primary neurons was significantly in-
creased after oxyHb-incubated for 48 h (Fig. 1c and d).
Double immunofluorescence assay further verified the
ICH-induced increase in the protein level of A1AR in
neurons (Fig. 1e). In addition, Jeong et al. reported that
astrogliosis participated in neuronal recovery in ATP-
injected brain [30]. To pursue the potential role of astro-
gliosis in A1AR action in this ICH model, we also tested
the protein level of A1AR in astrogliosis by double im-
munofluorescence. And the results showed that there was
no significant change in the protein level of A1AR in
astrogliosis between sham group and ICH group (Fig. 1f).
Finally, double immunofluorescence also showed that
oxyHb treatment could increase the protein level of A1AR
in cultured neurons (Fig. 1g). So, we focused on A1AR in
neurons in the following study.
A1AR activation suppressed caspase-3 activation and
albumin extravasation
We conducted further studies using the A1AR agon-
ist, N(6)-cyclohexyladenosine (R-PIA), and the A1AR
antagonist, 8-phenyl-1,3-dipropylxanthine (8-PT). Both
agonist and antagonist were administered 30 min be-
fore induction of ICH. Rats were randomly divided
into 4 groups: sham group, ICH group, ICH + R-PIA
group, and ICH + 8-PT group. We performed western
blot analysis at 48 h after ICH onsets and detected
changes in the protein levels of active caspase-3 and
albumin (Fig. 2a and b). Protein levels of active
caspase-3 and albumin showed significant increases in
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the ICH group compared with the sham group. Treat-
ment with the agonist R-PIA suppressed the ICH-
induced increase in levels of caspase-3 and albumin
(p < 0.05). In contrast, treatment with the A1AR an-
tagonist, 8-PT, enhanced ICH-induced upregulation of
caspase-3 and albumin protein levels (p < 0.05).
A1AR decreased neuronal death and degeneration and
relieved brain edema
We evaluated neuronal death and degeneration using
terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) and Fluoro-Jade B (FJB), re-
spectively. Rats subjected to ICH or ICH +DMSO dem-
onstrated histological evidence of neuronal death
compared with the sham group (Fig. 2c and d), while
there was no obvious differences observed between the
ICH and ICH +DMSO groups. The group pretreated
with R-PIA before ICH injury demonstrated a significant
decrease in cell death ratio in the rat brain sample. In
contrast, pretreatment with the A1AR receptor antagon-
ist 8-PT before ICH injury led to an increase in the
number of TUNEL-positive cells.
Fig. 1 Changes in adenosine receptor expression in vivo and in vitro. a Western blot analysis of adenosine receptor expression at different time
points following ICH in vivo. A1AR levels peaked at 48 h. b Quantification of the results in panel A. Bars represent relative protein levels. The
mean values of the protein levels in the sham group were normalized to 1.0. *p < 0.05 for the 48 h ICH group versus the sham group. c Western
blots of adenosine receptor expression in vitro. A1AR levels peaked at 48 h. d Quantification of the results in panel C. Bars represents relative
protein levels. The mean values of the protein levels in the control group were normalized to 1.0. *p < 0.05 for the 48 h OxyHb group versus the
control group. e and f Immunofluorescence in vivo. Double immunofluorescence analysis was performed with A1AR antibodies (green) and neuronal
or astrocyte marker (NeuN/GFAP, red), and nuclei were fluorescently labeled with DAPI (blue). Scale bar = 32 μm. G: Immunofluorescence in vitro.
Double immunofluorescence analysis was performed with A1AR antibodies (green) and neuronal marker (NeuN, red), and nuclei were fluorescently
labeled with DAPI (blue). Scale bar = 20 μm
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In addition, in ICH group, the number of FJB-positive
cells clearly increased compared with the sham group.
And the number of FJB-positive cells decreased signifi-
cantly in the ICH + R-PIA group and increased signifi-
cantly in the ICH + 8-PT group (Fig. 3a and b) (p < 0.05).
Brain water content was also examined at 48 h after
ICH and showed a significantly higher brain water con-
tent in brain samples of ICH group compared with
those in the sham group (Fig. 3c) (p < 0.05). And the
mean value of brain water content was decreased after
Fig. 2 Effects of A1AR on ICH-induced SBI. a Western blot analysis showing expression of A1AR, active caspase-3, and albumin in the sham, ICH,
ICH + R-PIA, and ICH + 8-PT groups at 48 h after ICH onsets. b Quantification of the results in panel A. The mean values of the protein levels in
the sham group were normalized to 1.0. *p < 0.05 for the ICH group versus the sham group, #p < 0.05 for the ICH + R-PIA group versus the ICH
group, & p < 0.05 for the ICH + 8-PT group versus the ICH group. c TUNEL staining showing effects of A1AR on SBI at 48 h after ICH onsets.
Representative images from sham, ICH, ICH + DMSO, ICH + R-PIA, and ICH + 8-PT groups. Each group was subjected to ICH except for the sham
group. Scale bar = 50 μm. d The percentage of TUNEL-positive neurons. *p < 0.05 for the ICH group versus the sham group, #p < 0.05 for the ICH
+ R-PIA group versus the ICH group, & p < 0.05 for the ICH + 8-PT group versus the ICH group
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administration of the A1AR agonist R-PIA (p < 0.05). In
contrast, after administration of the A1AR antagonist
8-PT, brain water content increased significantly. In
addition, we performed TUNEL studies in vitro (Fig. 3d
and e) and results were similar to those from in vivo
experiments.
As described above, these results suggested that
pharmacological activation targeting A1AR provided ef-
fective inhibition of brain injury that occur following
ICH.
A1AR increased phosphorylation levels of P38, MAPKAP2,
and Hsp27
To investigate the underlying mechanism by which
A1AR prevent ICH-induced SBI and whether MAPK
family participates in the process, the activation of
ERK, p38 and JNK was tested by western blot analysis.
Compared with sham group, the phosphorylation
levels of ERK, p38 and JNK all were increased at 48 h
after ICH onsets, suggesting ICH may induce the acti-
vation of ERK, p38 and JNK. In addition, R-PIA caused
a statistically significant increase in phospho- p38,
however, did not modify the phosphorylation of both
ERK and JNK. These results showed that protection
attained 48 h after ICH, by administration of A1AR ag-
onists, involves increased activation of p38 MAPK
(Fig. 4a-c).
Lee et al. have suggested that A1AR could exert a pro-
tective effect in transient renal ischemia through activa-
tion of the P38-MAPKAP2-Hsp27 pathway [31]. In this
Fig. 3 Changes in necrotic and apoptotic neurons, and brain water content after A1AR stimulation or inhibition. a FJB staining showing effects of
A1AR on SBI at 48 h after ICH onsets. Representative images from sham, ICH, ICH + DMSO, ICH + R-PIA, and ICH + 8-PT groups. Each group was
subjected to ICH except for the sham group. Scale bar = 50 μm. b Quantification of the FJB staining in each group. FJB-positive cells were counted per
unit area. *p < 0.05 for the ICH group versus the sham group, #p < 0.05 for the ICH + R-PIA group versus the ICH group, & p < 0.05 for the ICH + 8-PT
group versus the ICH group. c Brain water content of sham, ICH, ICH + R-PIA, and ICH + 8-PT groups at 48 h after ICH onsets. *p < 0.05 for the ICH
group versus the sham group, #p < 0.05 for the ICH + R-PIA group versus the ICH group, & p < 0.05 for the ICH + 8-PT group versus the ICH group.
d TUNEL staining to elucidate the role of A1AR in OxyHb-treated neurons in vitro. Representative images from control, OxyHb, OxyHb + DMSO, OxyHb
+ R-PIA, and OxyHb + 8-PT groups. Each group was subjected to OxyHb except for the control group. Scale bar = 20 μm. e The percentage of TUNEL-
positive cells. *p < 0.05 for the OxyHb group versus the control group, #p < 0.05 for the OxyHb + R-PIA group versus the OxyHb group
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study, compared with the sham group, remarkable in-
creases in the phosphorylation levels of MAPKAP2 and
Hsp27 were observed in the ICH group (p < 0.05), which
were further increased by R-PIA treatment and reversed
by 8-PT(p < 0.05) (Fig. 4b and c). Similar results were
also obtained in vitro (Fig. 4d and e).
Blocking P38 or Hsp27 inhibited the neuroprotective
effect of A1AR
We further investigated the role of P38/MAPKAP2/
Hsp27 in A1AR’s action using antagonists of p38
(SB203580) and Hsp27 (KNK437) (Fig. 4e and f). Fol-
lowing pretreatment with R-PIA before ICH, the
Fig. 4 The mechanisms underlying A1AR effects in SBI. a Western blot analysis showing phosphorylation level of ERK1/2 and JNK in the sham,
ICH, ICH + R-PIA, and ICH + 8-PT groups at 48 h after ICH onsets. b Western blot analysis showing expression of p-P38, p-Hsp27, and p-MAPKAP2
in the sham, ICH, ICH + R-PIA, and ICH + 8-PT groups. c Quantification of the results in panel b. The mean values of the protein levels in the sham
group were normalized to 1.0. *p < 0.05 for the ICH group versus the sham group, #p < 0.05 for the ICH + R-PIA group versus the ICH group, &
p < 0.05 for the ICH + 8-PT group versus the ICH group. d, e Western blot analysis showing expression of p-P38, p-Hsp27, and p-MAPKAP2 in vitro.
*p < 0.05 for the OxyHb group versus the control group, #p < 0.05 for the OxyHb + R-PIA group versus the OxyHb group, & p < 0.05 for the OxyHb
+ 8-PT group versus the OxyHb group. f Following treatment with the P38 (SB203580) and Hsp27 (KNK437) antagonists, we detected changes in
levels of p-P38, p-Hsp27, and p-MAPKAP2 in vivo at 48 h after ICH onsets. g Quantification of the results in panel f. The mean values of the
protein levels in the ICH group were normalized to 1.0. *p < 0.05 for the ICH + R-PIA group versus the ICH group, #p < 0.05 for the ICH + R-PIA
group versus the ICH + R-PIA + KNK group, & p < 0.05 for the ICH + R-PIA group versus the ICH + R-PIA + SB group
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phosphorylation levels of P38, MAPKAP2, and Hsp27
increased significantly compared with the ICH group (p
< 0.05). After blocking Hsp27, the phosphorylation level
of Hsp27 showed a significant decrease compared with
the R-PIA group, while the phosphorylation levels of
p38 and MAPKAP2 showed little change. After blocking
p38, the phosphorylation levels of P38, MAPKAP2, and
Hsp27 were all clearly decreased compared with the R-
PIA group (p < 0.05) (Fig. 4f and g). In addition, in the
presence of any of these antagonists, R-PIA -induced
A1AR activation could not effectively suppress neuronal
death and degeneration induced by ICH (Fig. 5a-d).
Thus, we speculated that A1AR exhibited a neuropro-
tective function, which might act through the P38-
MAPKAP2-Hsp27 pathway.
Finally, we used Evans blue (EB) to assess permeability
of the blood–brain barrier (BBB). The content of EB ex-
uded from blood vessels in different groups is shown in
Fig. 5e and f. Compared with the sham group, EB con-
tent in the brain increased significantly in the ICH group
(p < 0.05), which was significantly suppressed by R-PIA
treatment and aggravated by 8-PT treatment (p < 0.05).
And both SB203580 and KNK437 could abolish the pro-
tective effects of R-PIA on ICH-induced BBB dysfunction.
Discussion and Conclusions
Although the A2AR has been the subject of most previ-
ous studies (see Introduction), our results show that the
protein level of A1AR, but not A2A, A2B, or A3, was
significantly increased after ICH. In addition, we have
demonstrated that the A1AR agonist R-PIA could re-
duce ICH-induced SBI via modifying the activation of
p38, but not ERK1/2 and JNK. Base on these results, we
hypothesized here that adenosine is extensively gener-
ated from ATP released by ruptured red cell during ICH
and quickly activates its receptor, A1AR at least partially,
in neuron cells, and then elevated the activity of P38-
MAPKAP2-Hsp27 pathway, which exerts neuroprotec-
tive effect and suppresses ICH-induced EBI (Fig. 5g).
As firstly put forward by Drury in 1929, the concept of
purines as extracellular signaling molecules was ap-
proved. Extracellular purines (ATP, ADP, and adenosine)
have been proved to be involved in diverse biological
functions, including neurotransmission, smooth muscle
contraction, exocrine and endocrine secretion, inflam-
mation, the immune response, and platelet aggregation,
via cell-surface receptors termed purine receptors. As
early as minutes after ICH, extravasated blood compo-
nents and damage-associated moleculars, such as ATP
released from damaged and necrotic tissue, impose a
pro-oxidative, strong cytotoxic, and proinflammatory in-
sult toward adjacent viable brain cells [32]. And it has
been reported that, both in the ATP-injected substantia
nigra and cortex, ATP rapidly induced death of the
neurons and astrocytes in the injection core area within
3 h [30, 33]. Given the above evidence, the cytotoxic ef-
fects of ATP tend to occur at the early stage of ICH-
induced brain injury, which may be related to the narrow
therapeutic window for the acute phase of ICH. Fortu-
nately, the released ATP can be hydrolyzed extracellularly
by a variety of cell surface-located enzymes referred to as
ectonucleotidases. Extracellular ATP and ADP can be step
by step hydrolyzed to adenosine by ectonucleotide pyro-
phosphatase/phosphodiesterases (E-NPPs), ectonucleoside
triphosphate diphophohydrolases (E-NTPDases), and al-
kaline phosphatases (APs), while extracellular AMP is
substrate of ecto-5′-nucleotidase (eN) and APs [34]. As
the final product of hydrolysis cascade, adenosine and its
receptors attracted more and more attention. In this
study, we focused on the role of adenosine receptors in
ICH-induced SBI and the underlying mechanisms.
There are 4 adenosine receptor subtypes: A1AR,
A2aAR, A2bAR, and A3AR [35, 36]. Numerous authors
indiscriminately select A2aAR, and Lin et al. have shown
that an A2aAR agonist is effective in preventing vaso-
spasm in subarachnoid hemorrhage conditions by inhi-
biting eNOS expression in brain vessels and inducing
iNOS expression [37, 38]. However, in our time course
experiment, A2aAR did not increase as much as A1AR
after ICH. Thus, we selected A1AR for further study. In
addition, as shown in Fig. 2a and b, the protein level of
A1AR was increased to some extent under ICH, which
is enhanced by its agonists R-PIA and inhibited by its
antagonists 8-PT. Accordingly, R-PIA treatment allevi-
ated ICH-induced SBI, which was aggravated by 8-PT
treatment. The results are consistent with the previous
report about the correlation between the efficacy and
the expression of adenosine receptors [29] and suggest
that ICH-induced A1AR activation maybe a self-help
measure in neurons.
Many authors have suggested that A1AR activation
has a beneficial effect [39–41]. Lee et al. indicated that
endogenous A1AR activation produced cytoprotective
effects in the renal proximal tubule, and Kim found that
endogenous A1AR activation prevented murine liver is-
chemia reperfusion injury from worsening. However,
others also have suggested that blocking A1AR exerted
protection [42, 43]. In this study, we used R-PIA, a spe-
cific A1AR receptor agonist, to evaluate the role of
A1AR in neuronal function under ICH conditions. At
48 h, the numbers of apoptotic or necrotic cells were
clearly reduced in ICH groups pretreated with R-PIA
(Fig. 2 and 3). A positive effect of 8-PT on apoptosis and
necrosis was observed.
Lee demonstrated that endogenous A1AR activation
produced cytoprotective effects by modulating the P38-
MAPKAP2-Hsp27 pathway in renal cells [31]. However,
no one has reported such effects in ICH conditions. In
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our experiment, inhibition of P38 suppressed the upreg-
ulation of phosphorylation of P38, MAPKAP2, and
Hsp27, while the antagonist of Hsp27 (KNK437) clearly
inhibited upregulation of Hsp27 phosphorylation. And
both the two antagonists could almost completely abolish
R-PIA- mediated neuroprotective effect (Fig. 5). Thus,
these data suggest a crucial role for the P38-MAPKAP2-
Hsp27 pathway in ICH conditions. In support of this
Fig. 5 TUNEL, FJB, and EB results with antagonists for P38 and Hsp27, and proposed underlying mechanisms. a TUNEL staining showing
apoptotic cells in ICH, R-PIA, Hsp27 antagonist (KNK437), and P38 antagonist (SB203580) groups at 48 h after ICH onsets. Each group was
subjected to ICH. Double immunofluorescence analysis was performed with TUNEL (green) and a neuronal marker (NeuN, red), and nuclei
were fluorescently labeled with DAPI (blue). Arrows indicate TUNEL-positive neurons. Scale bar = 50 μm. b The percentage of TUNEL-positive
neurons in each group. *p < 0.05 for the ICH + R-PIA group versus the ICH group, #p < 0.05 for the ICH + R-PIA group versus the ICH + R-PIA +
KNK group, & p < 0.05 for the ICH + R-PIA group versus the ICH + R-PIA + SB group. c FJB staining showing FJB-positive cells in the ICH, R-PIA,
Hsp27 antagonist (KNK437), and P38 antagonist (SB203580) groups at 48 h after ICH onsets. Each group was subjected to ICH. Scale bar =
50 μm. d Quantification of the FJB staining in each group. FJB-positive cells were counted per unit area. *p < 0.05 for the ICH + R-PIA group
versus the ICH group, #p < 0.05 for the ICH + R-PIA group versus the ICH + R-PIA + KNK group, & p ˂ 0.05 for the ICH + R-PIA group versus the
ICH + R-PIA + SB group. e, f EB results for sham, ICH, ICH + R-PIA, ICH + 8-PT, ICH + R-PIA + KNK, and ICH + R-PIA + SB groups. *p < 0.05 for the
ICH group versus the sham group, #p < 0.05 for the ICH + R-PIA group versus the ICH group, @ p < 0.05 for the ICH + 8-PT group versus the ICH
group, $p < 0.05 for the ICH + R-PIA + KNK group versus the ICH + R-PIA group, &p < 0.05 for the ICH + R-PIA + SB group versus the ICH + R-PIA
group. G: Proposed mechanism for the role of A1AR in SBI
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concept, Carroll and Yellon have presented preliminary
results from a cardiac myoblast cell line showing that pre-
treatment with P38 MAPK inhibitor SB203580 completely
abolished delayed protection after ischemic- or adenosine-
induced preconditioning [44].
Hsp27, a member of the heat shock protein family, is a
molecular protein with diverse cytoprotective effects.
Van Why et al. [45] have demonstrated that Hsp27,
together with the actin cytoskeleton, restricts injury in
vitro. The preservation of cytoskeletal actin contributes
to architectural integrity of the cytoskeleton, at least in
part. Phosphorylation of Hsp27 maintains the integrity
of cells and enhances their ability to resist breaking
down after ATP depletion [46]. In addition, Hsp27, act-
ing as a molecular chaperone, prevents unfolded pro-
teins from irreversible aggregation, reduces oxidative
stress-mediated injury, and counteracts apoptosis by
interacting with caspases [47, 48]. We propose that in-
duction and increased phosphorylation of Hsp27 may
provide protection against necrosis as well as apoptosis
in neurons. In this study, we showed that activating
A1AR with agonist R-PIA increased the phosphorylation
level of Hsp27.
Finally, our experiments had limitations. The animals
were intraperitoneally injected with A1AR agonist R-PIA
and A1AR antagonist 8-PT. When these drugs crossed
the BBB and finally reached the brain, their biological
activity was limited. In addition, although there was no
significant cardiovascular complications of R-PIA and 3-
PT (see Methods), further pharmacological and toxicol-
ogy experiment is still urgently needed to eliminate
other potential side effects of them. In our experiment,
we used healthy Sprague–Dawley (SD) rats to mimic the
progression of ICH; however, in the clinic, we often see
older patients. Finally, in vitro, we only treated neurons
with oxyhemoglobin (OxyHb), and it remains to be de-
termined if it is appropriate for activation of A1AR.
In conclusion, the present study demonstrated that,
following ICH, the release of hematoma components,
such as adenosine, may induce an increase in the protein
level of A1AR, which maybe a self-help measure in neu-
rons. A1AR agonist R-PIA could significantly increase
the protein level of A1AR and alleviate ICH-induced SBI
via P38-MAPKAP2-Hsp27 pathway, while A1AR antag-
onist 8-PT exerts opposite effects. We thus propose
A1AR as a critical endogenous physiological regulator in
neurons and suggest it may be potential therapeutic tar-
get in the treatment of ICH.
Methods
Study design and experimental groups
Drug administration was shown in Fig. 6a-c. Briefly, R-
PIA, prepared in normal saline containing 20 % DMSO at
a concentration of 5 μg/ml, was injected intraperitoneally
at a dose range of μg/kg body weight. 8-PT was prepared
in normal saline containing 10 % DMSO at a concentra-
tion of 0.2 mg/ml and injected intraperitoneally at a dose
of 3 mg/kg body weight. KNK was prepared in DMSO at
a concentration of 2.5 μg/μl and injected intracerebroven-
tricularly at a dose of 16.7 μg/kg body weight [49]. 5 μl
SB203580 in normal saline containing 0.1 % DMSO at a
concentration of 1 mM were given via intracerebroven-
tricular injection [50]. All the drugs were administered
30 min before induction of ICH. To pursue the potential
toxic side effects of all the four drugs, we have treated nor-
mal rats with them at the same dosage of that used in this
study in preliminary experiments. No rat died in all the
groups. Blood pressure and heart rate were measured via
the cannulated right femoral artery. There were no signifi-
cant differences in blood pressure and heart rate among
vehicle group, R-PIA group, 8-PT group, KNK group, and
SB203580 group (Data not shown).
Antibodies
Anti-A1AR antibody (ab82477), anti-active caspase-3
(ab2302), Chk pAb to albumin (ab106582), Rb pAb to
MAPKAP2 (ab131531), Rb pAb to phosphor MAPKAP2
(ab63378), Ms mAb to Hsp27 (ab2790), Rb pAb to phos-
phor Hsp27 (ab5594), Rb mAb to NeuN (ab177487), anti-
ERK1 (phospho T202) + ERK2 (phospho T185) antibody
(ab201015), anti-ERK1 + ERK2 antibody (ab17942), anti-
JNK1 (phospho T183) antibody (ab47337), anti-JNK1 anti-
body (ab110724), anti-GFAP antibody (ab10062), and Ms
mAb to NeuN (ab104224) were purchased from abcam.
Anti-A2aAR antibody (sc-32261), anti-A2bAR antibody
(sc-28996), anti-A3AR antibody (sc-13938), β-actin (sc-
47778), and GAPDH (sc-365062) were purchased from
Santa Cruz. Rb pAb to P38, phosphor P38 was purchased
from Cell Signaling.
Establishing the ICH model
Adult male SD rats (0–300 g) were anesthetized with
4 % chloral hydrate, which was injected intraperitoneally
at a dose of 1 mL per 100 g. After the rat was fully anes-
thetized, it was fixed in a stereotactic apparatus frame
(Shanghai Ruanlong Science and Technology Develop-
ment Co., Ltd., Shanghai, China). Extra chloral hydrate
was injected if needed based on responses to tail
pinches. The rat was then placed supine on a heating
pad, which maintained temperature at approximately
27–35 °C. The experimental ICH model was produced
using stereotaxic insertion of a needle with a rounded
tip and a side hole into the basal ganglia [51, 52]. The
position of basal ganglia was 3.5 mm lateral to the mid-
line, 0.2 mm posterior to bregma, and 5.5 mm ventral to
the cortical surface. After the microinjector was in pos-
ition, collagenase IV was injected over 5 min, and the
needle was left in the brain for 5 min. Bone wax was
Zhai et al. Molecular Brain  (2016) 9:66 Page 9 of 13
used as needed to block the burr hole to prevent loss of
CSF and blood from the midline vessels. Next, we su-
tured the scalp and returned the rat to its cage where it
had free access to food and water. Representative brain
slices from the ICH model are shown in Fig. 6d. Assess-
ment of SBI was performed at 48 h after ICH onsets.
Western blot analysis
After brain tissues were collected, the brain tissue from
each rat was separately homogenized and lysed in ice-
cold RIPA lysis buffer (P0013; Beyotime, Shanghai,
China). After centrifuging at 12,500 × g for 15 min at 4 °
C, the supernatants were collected. A standard BCA
(Beyotime, P0012) method was used to determine pro-
tein concentration. Then, protein samples (100 mg/lane)
were loaded onto a 10 % SDS polyacrylamide gel, sepa-
rated, and electrophoretically transferred to a PVDF
membrane (IPVH00010; Millipore, Billerica, MA, USA).
The membrane was blocked in 5 % nonfat milk for 2 h
at 37 °C. Next, the membrane was incubated with the
primary antibody overnight at 4 °C and then with the
horseradish peroxidase-linked secondary antibody for
Fig. 6 Experimental protocols. a Experiment 1 was designed to evaluate expression of A1AR. b Experiment 2 was designed to investigate the role
of A1AR in ICH-induced SBI. c Experiment 3 was designed to elucidate mechanisms underlying the effects of A1AR. d Representative whole brains
and brain slices from ICH model rats at each time point
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1.5 h at 37 °C. The membrane was washed with PBST
and visualized using enhanced chemiluminesence detec-
tion (3100 Mini; Clinx Science Instruments Co.). The
relative quantities of proteins were analyzed using Image
J software.
Immunofluorescence microscopy
We performed double labeling for A1AR, A2aAR,
A2bAR, and A3AR with NeuN, to detect expression of
A1AR, A2aAR, A2bAR, and A3AR in neurons. The sec-
tions were incubated with primary antibody, including
antibodies for A1AR, A2aAR, A2bAR, A3AR, and NeuN
antibody-neuronal cell marker (all diluted 1:100), over-
night at 4 °C. Then, secondary antibodies were added,
followed by washing 3 times with PBS. Secondary anti-
bodies were Alexa Fluor 488 donkey anti-rabbit IgG
antibody and Alexa Fluor 555 donkey anti-mouse IgG
antibody (Life Technologies, Carlsbad, CA, USA, 1:300
dilution). After a final wash, sections were coverslipped
with an anti-fading mounting medium containing 4,6-
diamino-2-phenyl indole (DAPI, SouthernBiotech, Bir-
mingham, AL, USA). Normal rabbit IgG and normal
mouse IgG were used as negative controls for immuno-
fluorescence assays (data not shown). Sections were ob-
served with a fluorescence microscope (Olympus, BX50/
BX-FLA/DP70, Olympus Co., Japan). The relative fluor-
escence intensity was analyzed using Image J.
TUNEL staining
Brain tissues embedded in paraffin were used for
TUNEL staining. The sections were deparaffinized,
dehydrated by heating at 75 °C in an oven for 60 min,
and then rehydrated through xylenes and graded ethanol
solutions to water. The sections were then incubated in
Triton X-100 for 10 min. After 3 washes in PBS (5 min
per wash), the sections were incubated with the TUNEL
reaction mixture for 1 h at 37 °C. Sections were once
again washed 3 times in PBS (5 min per wash). After the
final wash, sections were coverslipped with an anti-
fading mounting medium containing DAPI. The number
of TUNEL-positive neurons in each millimeter length
was counted carefully per sample. Cell counts from the
brain were averaged to provide the mean value.
FJB
Cell necrosis in brain tissue was detected by FJB. FJB
procedures were identical to those for TUNEL. Sections
were deparaffinized, dehydrated in an oven, rehydrated
through xylenes and graded ethanol solutions to water,
and permeabilized in 0.04 % Triton X-100. Sections were
then incubated in FJB dye solution. The sections were
visualized by a fluorescence microscope (Olympus
BX50/BXFLA/DP70; Olympus). The FJB-positive cells
were counted by an observer who was blind to the
experimental groups. To evaluate the extent of cell ne-
crosis, the necrotic index was defined as the average
number of FJB-positive cells in each section counted in
6 microscopic fields (×400 magnification).
Brain edema
Rats were randomly divided into 4 groups: sham, ICH,
R-PIA (7.5 g dissolved in 1.5 mL DMSO and NaCl solu-
tion) [53], 8-PT(0.9 mg dissolved in 4 mL DMSO and
NaCl solution) [54]. The index of brain edema was eval-
uated using the wet/dry method. Briefly, after brain tis-
sue was removed, the samples were collected and
weighed immediately (wet weight), dried at 100 °C for
72 h, and then weighed again (dry weight). The percent-
age of water content was calculated as [(wet weight-dry
weight)/wet weight] × 100 %.
EB detection
BBB injury was determined by EB (Sigma-Aldrich, St
Louis, MO, USA) extravasation. Briefly, EB (2 % in Nor-
mal saline, 2 mL/kg) was injected into the rat through
the femoral vein 48 h after ICH, and it was allowed to
remain in circulation for 1 h. Animals were then rea-
nesthetized and perfused using PBS to wash intravascu-
lar EB dye. A 3 mm of the brain tissue (coronal plane)
were taken and it was divided into four parts: left
cortical, right cortical, left basal, right basal. The samples
were incubated in 5 % TCA and centrifuged at
15,000 rpm for 10 min. The supernatant was collected
and mixed with ethanol. Absorbance at 620 nm was
measured in a spectrophotometer.
Primary neuron-enriched cultures
Whole brains of 1-day-old pups (from pregnant SD rats)
were used to prepare primary neuron-enriched cultures.
We tried as much as possible to minimize the number of
pups used and their suffering. In brief, we first removed
the meninges and blood vessels of the brain. The brain tis-
sues were then digested with 0.% trypsin for 5 min, and
the digestion was terminated by washing the tissue 3 times
with PBS. The brain tissue suspension was centrifuged at
500 × g for 5 min, and the pellet was resuspended in
DMEM/F12 medium containing 10 % heat-inactivated
fetal bovine serum, 1 mM sodium pyruvate, 2 mM L-glu-
tamine, 100 mM nonessential amino acids, 50 U/mL peni-
cillin, and 50 mg/mL streptomycin (all from GIBCO,
Carlsbad, CA, USA). Finally, cells were seeded in 150-cm2
culture flasks in fresh medium. Afterwards, half of the
medium was changed every 2 d. In general, approximately
2 weeks after the initial seeding, a confluent monolayer of
neurons was achieved. Neurons were separated from the
brain tissue by shaking the flask for 4 h at 150 rpm, col-
lected by centrifugation, and re-seeded in 12-well plates
with fresh DMEM/F12 medium.
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Treatments of neurons
Enriched neurons were divided into 5 groups: control,
OxyHb, OxyHb + vehicle (DMSO, Sigma-Aldrich), OxyHb
+ R-PIA (Sigma-Aldrich), and OxyHb + 8-PT (Sigma-Al-
drich). Forty-eight hours after neuron re-seeding, cells
were treated with OxyHb (at a final concentration of
10 μM), DMSO (volume equal to R-PIA and 8-PT), R-PIA
(at a final concentration of 100 nM) [39], or 8-PT (at a final
concentration of 100 nM) in fresh medium. After incuba-
tion for 48 h (37 °C, 5 % CO2), the cell medium was re-
moved. Cells were then washed 3 times in PBS and fixed
with 4 % paraformaldehyde.
Statistical analysis
Values are presented as means ± SEM. SPSS 11.5 (SPSS
Inc., Chicago, IL, U.S.) was used for statistical analysis.
The Mann–Whitney U test was used to compare behav-
ior and activity scores among groups. Statistical compar-
isons between groups were performed using one-way
analysis of variance followed by either a Dunnett’s or a
Tukey’s post hoc test, the former for comparisons to a sin-
gle control group, the latter to compare across multiple
groups. Mortality was compared with a w2 test. A prob-
ability of P < 0.05 was considered statistically significant.
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